2014 ACRUX AGM 27/11/14 from the chairman:
The viability of our process was proven during the development of the two projects with Hexima. We are confident that the new intellectual property developed jointly with Hexima and other intellectual property independently owned by Acrux will create significant shareholder value.
Financial Report half year ended 31 December 2014 – 26/02/15
The Directors regularly review projects and will update the market when progress is made. The two Hexima projects remain on hold, pending resolution of our dispute.
Financial Report full year ended 30 June 2015 – 13/08/15
the result of investment in the consolidated entities strategy coupled with legal costs incurred in the dispute with Hexima.
2015 Annual Report
We continue to progress development of an antifungal therapeutic for onychomycosis. Subject to the results
of work currently being undertaken as part of the development program, new intellectual property is expected to be generated. In a separate initiative, we have made significant progress with superior formulations of two nonsteroidal anti-inflammatory drugs.
So nothing regarding what the terms of the final agreement were, who got what as far as the IP or R&D benefits that had accrued to date and what if any payments were required by either party.
- Forums
- ASX - By Stock
- 2018 Investor Conference Call
2014 ACRUX AGM 27/11/14 from the chairman: The viability of our...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACR (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.5¢ |
Change
0.002(3.77%) |
Mkt cap ! $15.98M |
Open | High | Low | Value | Volume |
5.4¢ | 5.5¢ | 5.4¢ | $1.564K | 28.62K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10999 | 5.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.8¢ | 17258 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10999 | 0.054 |
2 | 132074 | 0.053 |
1 | 168669 | 0.052 |
3 | 119539 | 0.051 |
2 | 217490 | 0.050 |
Price($) | Vol. | No. |
---|---|---|
0.058 | 17258 | 1 |
0.059 | 18000 | 1 |
0.060 | 670 | 1 |
0.061 | 100000 | 1 |
0.062 | 116100 | 2 |
Last trade - 14.05pm 10/10/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online